These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38906111)

  • 1. NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.
    Zhu X; Li Y; Liu H; Wang Y; Sun R; Jiang Z; Hou C; Hou X; Huang S; Zhang H; Wang H; Jiang B; Yang X; Xu B; Fan G
    Cell Chem Biol; 2024 Jun; 31(6):1203-1218.e17. PubMed ID: 38906111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
    Lu T; Chen F; Yao J; Bu Z; Kyani A; Liang B; Chen S; Zheng Y; Liang H; Neamati N; Liu Y
    J Med Chem; 2024 May; 67(10):8099-8121. PubMed ID: 38722799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
    Yin C; Jia S; Yang X; Wu L
    Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
    Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
    Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation.
    Zhu X; Liu H; Chen L; Wu C; Liu X; Cang Y; Jiang B; Yang X; Fan G
    Cell Chem Biol; 2022 Nov; 29(11):1616-1629.e12. PubMed ID: 36323324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
    Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
    Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
    Olesen UH; Hastrup N; Sehested M
    APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT.
    Cheng J; He S; Xu J; Huang M; Dong G; Sheng C
    J Med Chem; 2022 Dec; 65(23):15725-15737. PubMed ID: 36442664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
    Cole J; Guiot MC; Gravel M; Bernier C; Shore GC; Roulston A
    Oncotarget; 2017 Sep; 8(44):77846-77859. PubMed ID: 29100430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugtamer-PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy.
    He S; Fang Y; Zhu Y; Ma Z; Dong G; Sheng C
    Adv Sci (Weinh); 2024 Jul; 11(25):e2401623. PubMed ID: 38639391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
    Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
    J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
    Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
    Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
    Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
    Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase.
    Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
    Nomura M; Ohuchi M; Sakamoto Y; Kudo K; Yaku K; Soga T; Sugiura Y; Morita M; Hayashi K; Miyahara S; Sato T; Yamashita Y; Ito S; Kikuchi N; Sato I; Saito R; Yaegashi N; Fukuhara T; Yamada H; Shima H; Nakayama KI; Hirao A; Kawasaki K; Arai Y; Akamatsu S; Tanuma SI; Sato T; Nakagawa T; Tanuma N
    Nat Commun; 2023 Dec; 14(1):8095. PubMed ID: 38092728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.